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OBJECTIVE: The INTERCEPT Blood System (IBS) for
platelets has been developed to reduce pathogen trans-
mission risks during platelet transfusions. This study
assessed the cost-effectiveness of using single-donor
platelets (SDP) and random-donor platelets (RDP)
processed with a pathogen inactivation treatment
(SDP+IBS and RDP+IBS) during orthopedic surgery,
which accounts for approximately 10% of platelets usage
in the U.S. METHODS: A decision-analytic model was
developed to simulate the possible transfusion-related
events and outcomes in three reference patients: a female
aged 60, 70, or 80 years, and undergoing a total hip
arthroplasty. Avoidance of pathogen exposure to HIV,
HCV, HBV, HTLV-I, and transfusion-related sepsis (TRS)
was incorporated in the model. Clinical outcomes were
measured by quality adjusted life-year gained (QALYs).
The direct medical costs of IBS and transfusion-related
complications were incorporated in the baseline model.
No indirect costs (e.g., work productivity losses) or trans-
fer costs (litigation) were considered. Possible beneﬁt on
reducing emerging pathogens risk was explored by incor-
porating a hypothetical HCV-like pathogen into sensitiv-
ity analyses. RESULTS: The incremental cost per QALY
gained of using SDP+IBS vs. untreated SDPs, ranged 
from $1,686,000 (at age 60)–$3,362,000 (at age 80).
Corresponding ﬁgures for RDP+IBS vs. RDPs, ranged
from $642,000–$1,404,000. Inclusion of an emerging
pathogen beneﬁt signiﬁcantly improved the cost effec-
tiveness to $423,000–$1,304,000 for SDP and
$66,000–$237,000 for RDP. Sensitivity analysis showed
that results were most sensitive to reductions in platelet
yield and case fatality rate from bacteria contamination,
but less sensitive to viral transmission risks. CONCLU-
SIONS: The cost-effectiveness of IBS in orthopedic
surgery patients appears to be comparable to that of other
widely accepted blood safety interventions (e.g. NAT
testing). Therefore, pathogen inactivation with the IBS 
for platelets should be considered to be a relatively cost-
effective strategy to improve the safety of platelet trans-
fusions and a potential insurance against the threat of
emerging pathogens.
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OBJECTIVES: In the last 25 years, the number of clini-
cal conditions Stem Cell Transplantation (SCT) is used as
a therapeutic intervention has been growing remarkably.
The emphasis in this study is on the management,
resources and economics of bleeding associated with SCT
in Germany and the United States, and the understand-
ing of the potential economic impact of NovoSeven® in
the management of such bleed. METHODS: A detailed
literature review was undertaken on bleeds associated
with SCT. Additional data were obtained from clinicians
at two leading SCT centres in Germany and one in the
United States. Resource utilisation, outcomes and cost
data were obtained from multiple sources including the
participating clinicians, local economists and personal
communications. Economic modelling techniques were
used to assess the potential impact of the addition of
NovoSeven® on current management practices.
RESULTS: In Germany, autologous, allogenic (family
related), and allogenic (un-related) SCT cost on average
€83,302, €115,954 and €172,522, respectively. The cor-
responding costs in the United States are: $84,583,
$202,474, and $303,159. Costs in the United States are
generally higher than in Europe. The additional costs of
bleeds depend on bleed site and severity. In Germany the
baseline costs of gastrointestinal and intracranial bleeds
are €32,085 and €8,684 respectively, with the addition of
NovoSeven® and associated reduction in the use of other
health care resources costs were €32,431 and €14,057. 
In the USA, the costs of bleeds vary from $5,718 to
$209,910. The additional cost of NovoSeven® may be
compensated for by a reduction in the use of blood 
products and inpatient hospitalisation. CONCLUSIONS:
Our results suggest that NovoSeven® might lead to cost
savings in certain bleeds. However, given the limited
number of bleeds managed with NovoSeven® in the
present study these results should be interpreted with
caution.
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OBJECTIVES: Treatment of severe hemophilia patients
has considerable economic implications, especially with
